Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of BI 409306 and Microgynon in Healthy Korean Females
NCT03193307Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osoresnontrine in Alzheimer's disease (AD) and schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at Day 29, Maximum Measured Concentration of BI 409306 in Plasma at Day 29 and 4 more. Started Jun 2017; status: completed.
02
Drugs
osoresnontrine
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NCT03193307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193307.